Clinical research and clinical trials are vital in the development and evaluation of new diagnostics, vaccines, and therapeutics for infectious disease. Once one of these interventions has been tested in clinical trials and is proven safe and effective in humans, it may be considered for licensure. DMID is responsible for supporting extramural clinical research to control and prevent diseases caused by a variety of human infectious agents. Spanning the pipeline from clinical science and product development to research studying optimal utilization strategies, DMID has a number of programs dedicated to advancing clinical research.
Since 2005, DMID has invested approximately $240 million per year to support clinical research on more than 115 pathogens, including those causing severe diarrhea, skin infections, and respiratory illnesses. Of the 770 supported projects, 42 percent include an international component. Together, the clinical research program addresses tuberculosis, malaria, antimicrobial resistance, international and tropical infectious diseases, sexually transmitted diseases, enteric pathogens, bacterial and viral respiratory pathogens, influenza research and surveillance, and biodefense product development.
For more information on the DMID clinical research program, please see
Last Updated March 11, 2014
Last Reviewed February 07, 2011